+

WO1999008659A1 - Procede pour ameliorer l'ecoulement et la compression de compositions de fabrication de comprimes - Google Patents

Procede pour ameliorer l'ecoulement et la compression de compositions de fabrication de comprimes Download PDF

Info

Publication number
WO1999008659A1
WO1999008659A1 PCT/US1998/017069 US9817069W WO9908659A1 WO 1999008659 A1 WO1999008659 A1 WO 1999008659A1 US 9817069 W US9817069 W US 9817069W WO 9908659 A1 WO9908659 A1 WO 9908659A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrochloride
agents
tableting
matrix
shearform
Prior art date
Application number
PCT/US1998/017069
Other languages
English (en)
Inventor
Pradeepkumar P. Sanghvi
Tushar K. Misra
Original Assignee
Fuisz Technologies Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuisz Technologies Ltd. filed Critical Fuisz Technologies Ltd.
Priority to AU90220/98A priority Critical patent/AU9022098A/en
Priority to JP2000509399A priority patent/JP2002518291A/ja
Priority to EP98942091A priority patent/EP0996427A1/fr
Priority to CA002301282A priority patent/CA2301282A1/fr
Publication of WO1999008659A1 publication Critical patent/WO1999008659A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Definitions

  • the present invention relates to fiowable tabletable compositions formed from shearform matrices which have cohesive properties due to the use therein of specific ingredients and subjecting some to certain process conditions. Chewable products can be made using these compositions and methods. RELATED APPLICATIONS
  • Co-pending and co-assigned PCT Application No. PCT/US 95/07194, filed June 6, 1995 also discloses a process and apparatus for making rapidly dissolving dosage units such as tablets by flash-flow processing. Cohesiveness and binding properties are critical to compositions intended to be used for discrete dosage units, such as tablets. Binding additives, such as glycerine, have been used in flash-flow matrices to provide self-binding properties. The addition of glycerine renders the shearform matrix cohesive and serves to bind the structure together.
  • U.S.S.N. 08/914,972, filed August 20, 1997 discusses the use of added glycerine. Its disclosure is hereby incorporated by reference. The use of glycerine in the matrix has its disadvantages, however, in that processing of such matrices in conventional tableting machinery has been difficult due to sticking of the composition to the tableting equipment and due to poor flow of the composition through the equipment.
  • the present invention uses unique materials and processing means to address the problems encountered when tableting shearform matrices containing added binding materials, such as glycerine, or those made from sugar alcohol ingredients.
  • Flash-flow processing typically begins with solid starting materials.
  • the original material then undergoes an instantaneous change during flash flow processing.
  • the resultant amorphous material generally a floss
  • the use of added glycerine or cohesivity enhancing ingredients in the floss component of tableting composition has generally precluded the use of conventional high speed tableting processes.
  • the invention is concerned with fiowable tabletable compositions and with rapid dissolve and chewable products made therefrom.
  • the overall procedure by which products are made using the invention involves three essential steps: (1) preparing a cohesive, free-flowing tabletable composition based upon a shearform matrix and containing at least one bio-affecting agent, at least one crystallization modifier, and employing at least one of: (a) a binding additive, and (b) a sugar alcohol ingredient; (2) densifying and milling that composition; and (3) -compressing it to form tablets.
  • Other techniques e.g., drying and sieving steps, can be used at various points in the overall procedure.
  • Antacid agents e.g., calcium carbonate, vitamins, e.g., Vitamins C and D, and NSAID s, e.g., ibuprofen, acetominaphin and mixtures containing same are among the preferred bio-affecting agents.
  • the tabletable compositions used in step (1) are produced via the use of one or both of (a) a binding additive and (b) particular component(s) in the matrix.
  • the binding additive (a) of the invention is generally added to the matrix after it is produced.
  • Useful additives include water, glycerine, sorbitol, mannitol, xylitol and the like, with glycerine preferred. Mixtures can be used.
  • ingredients (b) which can be employed in making matrices in accordance with the invention include certain sugar alcohols and other substances which tend to lend hygroscopic properties to the matrix produced therefrom. Among these are maltitol, mannitol, sorbitol and xylitol. Xylitol and sorbitol are preferred floss components.
  • the floss After the floss is made it may be treated with one or more crytallization modifiers, eg., ethanol and one or more glidants, eg., lactose. It is usually chopped before compression.
  • crytallization modifiers eg., ethanol
  • glidants eg., lactose
  • the treated floss is then compressed.
  • the compression step includes shaping the densified and milled formulations to yield tablets whose surfaces are tailored to be readily fractured during chewing. These chewable tablets typically have hardness values of about 6.0 to 30.0 pounds (i.e., 3.0 to 15.0 SCU's), preferably about 10 to about 12 pounds.
  • the process of the present invention permits the use of shearform matrices which are highly hygroscopic and inclined to transform from their amorphous state to a recrystallized state.
  • binding materials such as binding additives and/or sugar alcohol constituent(s)
  • shearform matrices to be used to produce tablets at both low and high pressures, i.e., under 500 psi and up to 8,000 psi, which tablets have excellent structural integrity, yet also exhibit exceptional dissolution characteristics as compared to conventional tablets.
  • the ability to dissolve rapidly when placed in the mouth is of great importance to the pharmaceutical industry, especially where patient compliance is of concern.
  • Rapidly dissolving tablets are difficult to manufacture, especially on commercial high speed tableting equipment, because the compression forces required to produce a high quality tablet are often so high that the decreased tablet porosity does not permit rapid penetration of fluids.
  • tableting formulations often require various tableting excipients such as lubricants, flow aids, glidants and the like, which help the formulations flow into the tablet dies and which also help produce quality tablets of the requisite density and hardness. These materials, however, can also affect dissolution rates.
  • Applicants have discovered that when they subject a substantially amorphous composition containing a shearform matrix made with either (a) a binding material, or (b) sugar alcohol constituent(s), to a compaction and densification process prior to tableting, the resultant amorphous shearform matrix loses its surface stickiness.
  • the glycerine As a result of the compaction of a glycerine treated shearform matrix, the glycerine is uniformly distributed throughout the matrix, then occluded from the surface and internalized in the amorphous matrix carrier to become densified therein.
  • shearform matrices made from feedstocks containing one or more of certain sugar alcohols — with optional subsequent treatment with binding additives ⁇ are mixed with conventional pharmaceutical ingredients, then compacted and densified. The densified mass is then milled to form particles which are free flowing, yet cohesive and self-binding when subjected to tableting forces. Tablets made from such free flowing particles using conventional tableting machinery, e.g. at about 1,500 to about 8,000 psi, exhibit dissolution at extremely rapid rates when placed in the mouth and optionally chewed. Typically, the tablets dissolve within 30 seconds or less, preferably 20 seconds or less.
  • any liquid binder present is forced into the interstices of the matrix fiber network, where it remains. Once any liquid binder material is forced to penetrate the floss network and become sorbed therein, it is effectively removed from the exposed floss surface, causing floss particles formed from the subsequent milling step to be free flowing.
  • compositions on sugar alcohol-containing matrices are treated in the absence of liquid binder(s), the compacting and densifying steps serve to eliminate much of the floss' "stickiness" and make milled floss particles free flowing.
  • the resultant particles of tableting composition are suitable for use in conventional tableting equipment because they are free flowing and resist sticking. Yet compositions containing these free flowing particles retain their ability to form a cohesive tablet by virtue of the binder additives which reside within the granules and/or are constituents of the matrix particles. The matrix particles then function to bind adjacent particles together under the compression forces of tableting.
  • a method of forming a fiowable feedstock having cohesive properties includes providing a mixture of shearform matrix and a binding additive, the combination of which would ordinarily be difficult to process using conventional tableting equipment due to the sticking and/or resistance to the flow of the composition in the tableting equipment.
  • the mixture of shearform matrix and binding additive is then densified to uniformly localize the binding material into the matrix and to form a compacted mass therefrom. This mass is then milled to form fiowable particles.
  • the tableting composition Once the tableting composition has been subjected to these processing steps, it can be used in conventional commercially available tableting equipment, i.e., high speed tableting equipment, without concerns for sticking, blocking or other similar disadvantages traditionally encountered with such shearform compositions.
  • a method of converting a mixture having self-agglomerating properties into a blend having free flowing properties includes compacting a mixture of self-agglomerating matrix particles, bio-affecting agent, crystallization modifier, and binding additive, to form a compacted mass. This compacted mass is then milled to form a free flowing particulate blend. Once the free flowing particulate blend has been formed, it can be incorporated into a tableting composition and used in conventional tableting equipment without encountering the sti eking and/or flow concerns of the same compositions which have not been subjected to the above-mentioned process steps.
  • a free flowing particulate feedstock blend formed from a self-agglomerating, sticky mixture of shearform matrix and binder, said self-agglomerating mixture having been subjected to compaction to form a compacted mass and subsequently to sizing of said compacted mass to form said free flowing particulate feedstock blend.
  • the shearform matrices used herein are based upon carriers selected from the group consisting of: monosaccharides, disaccharides, polydextrose, maltodextrin, oligo- saccharides and mixtures thereof. Mono- and disaccharides, such as sugars, are generally used as carriers.
  • the binding additives useful in the present invention include water, glycerine, xylitol, sorbitol, mannitol and combinations thereof, as well as other materials which are useful in providing cohesiveness and binding due to the stickiness they naturally impart to the carrier component. Amounts of about 1.0 to about 5.0% are useful. Glycerine is the preferred binding additive.
  • the feedstock ingredients which function as binding materials are one or more of xylitol, sorbitol and mannitol.
  • Xylitol and sorbitol, and combinations thereof, are preferred floss constituents.
  • Combinations in which the ratio of sorbitol to xylitol is about 1 :0.1 to 1 :1.0 are preferred combinations.
  • Mannitol, sorbitol or xylitol can be used alone.
  • the processes of the present invention focus on one or more of: (a) uniformly localizing the binding additive(s) under the surface of particles in the uncured shearform matrix, causing the stickiness associated with the binder to be entrapped within the matrix mass, leaving the surface substantially free of sticky character; and (b) treating an uncured shearform matrix, produced from a feedstock containing xylitol, sorbitol and/or mannitol to compact and densify it and eliminate stickiness.
  • Suitably compacted/densified feedstocks are in the form of free flowing particles having self-binding and cohesive properties such that useful tableting compositions can be made therefrom.
  • the free flowing particles formed in the present invention can be processed on conventional tableting equipment, i.e. using high speeds and ambient conditions.
  • compositions and processes for preparing bioaffecting products. Unless stated otherwise, all percentages recited are weight percentages, based on total composition weight.
  • compositions of the invention employ shearform matrix particles made using either or both of (a) a binding additive and (b) a sugar alcohol constituent.
  • the matrix particles are produced from feedstocks containing one or more saccharides. While simple sugars, e.g., sucrose, are preferred constituents, other ingredients, such as polydextrose can be used in the feedstock.
  • the self-binding and cohesive properties of the tablet formulations herein are augmented by the use of at least one sugar alcohol as a constituent of the feedstock from which the matrix is made.
  • at least one sugar alcohol as a constituent of the feedstock from which the matrix is made.
  • Maltitol, mannitol, sorbitol and xylitol can be used, with sorbitol and xylitol preferred.
  • one or more of the cohesivity enhancing sugar alcohols are used at concentrations of about 10% or more, with amounts of about 10% to about 50% of the feedstock being useful.
  • the matrix feedstock may optionally include one or more conventional pharmaceutical and/or tabletting additives.
  • One preferred additive is Polysorbate 80, ('TWEEN 80"), a surfactant.
  • the tablet compositions contain optional binding additives, preferably glycerine, in amount of about 0.5% to about 20%, preferably 0.5% to 5%.
  • Tableting compositions might employ bioaffecting agents, such as pharmaceutical agents and the like, which are preferably added in the form of uniform microspheres.
  • bioaffecting agents such as pharmaceutical agents and the like, which are preferably added in the form of uniform microspheres.
  • the active ingredients useful herein can be selected from a large group of therapeutic agents.
  • Respective classes include those in the following therapeutic categories: ace-inhibitors; alkaloids; antacids; analgesics; anabolic agents; anti-anginal drugs; anti-allergy agents; anti-arrhythmia agents; antiasthmatics; antibiotics; anticholesterolemics; anticonvulsants; anticoagulants; antidepressants; antidiarrheal preparations; anti-emetics; antihistamines; antihypertensives; anti-infectives; anti- inflammatories; antilipid agents; antimanics; anti-migraine agents; antinauseants; antipsychotics; antistroke agents; antithyroid preparations; anabolic drugs; antiobesity agents; antiparasitics; antipsychotics; antipyretics; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulcer agents; anti-uricemic
  • Active agents which may be used in the invention include: acetaminophen; acetic acid; acetylsalicylic acid, including its buffered forms; acrivastine; albuterol and its sulfate; alcohol; alkaline phosphatase; allantoin; aloe; aluminum acetate, carbonate, chlorohydrate and hydroxide; alprozolam; amino acids; aminobenzoic acid; amoxicillin; ampicillin; amsacrine; amsalog; anethole; ascorbic acid; aspartame; astemizole; atenolol; azatidine and its maleate; bacitracin; balsam peru; BCNU (carmustine); beclomethasone diproprionate; benzocaine; benzoic acid; benzophenones; benzoyl peroxide; benzquinamide and its hydrochloride; bethanechol; biotin; bisacodyl; bismuth subsalicylate; born
  • Particularly useful active agents include H 2 antagonists, analgesics, including non- steroidal anti-inflammatory drugs (NSAIDs), anticholestero- lemics, anti-allergy agents, and anti-migraine agents.
  • Analgesics include aspirin, acetaminophen, acetaminophen plus caffeine, and non- steroidal anti-inflammatory drugs (NSAIDS), e.g., ibuprofen and nimesulide.
  • Useful NSAIDs include ibuprofen; diclofenac and its alkali metal salts; fenoprofen and its metal salts; fluriprofen; ketoprofen; naproxen and its alkali metal salts; nimesulide; and piroxicam and its salts.
  • H 2 -antagonists which are contemplated for use in the present invention include cimetidine, ranitidine hydrochloride, famotidine, nizatidine, ebrotidine, mifentidine, roxatidine, pisatidine and aceroxatidine.
  • Useful anti-allergy agents include hydricodone and its tartrates; clemastine and its fumarate; azatadine and its maleate; acetaminophen; hydroxyzine and its pamoate and hydrochloride salts; chlo ⁇ heniramine and its maleates and tannates; pseudoephedrine and its sulfates and hydrochlorides; bromopheniramine and its maleate; dextrometho ⁇ han and its hydrohalides; loratadine; phenylephrine and its tannates and hydrochlorides; methscopolamine and its nitrates; phenylpropanolamine and its hydrochlorides; codeine and its hydrochloride; codeine and its phosphate; terfenadine; acrivastine; astemizole; cetrizine and its hydrochloride; phenindamine and its tartrate; tripelennamine and its hydrochloride;
  • Useful antimigraine agents include divalproex and its alkali metal salts; timolol and its maleate; propanolol and its hydrohalides; ergotamine and its tartrate; caffeine; sumatriptan and its succinate; dihydroergotamine, its hydrogenates/mesylates; methsergide and its maleate; isometheptene mucate; and dichloralphenazone.
  • antiemetics Another class of drugs which can be used are antiemetics.
  • Useful antiemetics include: meclizine and its hydrochloride; hydroxyzine and its hydrochloride and pamoate; diphenhydramine and its hydrochloride; prochlo ⁇ erazine and its maleate; benzquinamide and its hydrochloride; granisetron and its hydrochloride; dronabinol; bismuth subsalicylate; promethazine and its hydrochloride; metoclopramide and its halides/hydrates; chlo ⁇ romazine; trimethobenzamide and its hydrochloride; thiethylperazine and its maleate; scopolamine; pe ⁇ henazine; and ondansetron and its hydrochloride.
  • antidiarrheals such as Immodium AD, antihistamines, antitussives, decongestants, vitamins, and breath freshners.
  • anxiolytics such as Xanax; antipsychotics such as Clozaril and Haldon; antihistamines such as Seldane, Hismanal, Relafen, and Tavist; antiemetics such as Kytril and Cesamet; bronchodilators such as Bentolin, Proventil; antidepressants such as Prozac, Zoloft, and Paxil; antimigranes such as
  • ACE-inhibitors such as Vasotec, Capoten and Zestril
  • Anti-Alzheimers agents such as Nicergoline
  • Ca -Antagonists such as Procardia, Adalat, and Calan.
  • statins e.g., lovastatin, provastatin and the like are notable.
  • ingredients which may be included are flavors, fragrances, dyes, sweeteners both artificial and natural, and other additives.
  • fillers may be used to increase the bulk of the tablet.
  • Some of the commonly used fillers are calcium sulfate, both di- and tri basic, starch, calcium carbonate, microcrystalline cellulose, modified starches, lactose, sucrose, mannitol, and sorbitol.
  • Flavors may be chosen from natural and synthetic flavoring liquids.
  • An illustrative list of such agents include volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins and extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
  • a non-limiting representative list of examples includes citrus oils such as lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, grape, strawberry, raspberry, cherry, plum, pineapple, apricot or other fruit flavors.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits), aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond), 2,6-dimethyloctanal (green fruit), and 2-dodecenal (citrus, mandarin), mixtures thereof and the like.
  • aldehydes and esters such as benzaldehyde (cherry, almond), citral, i.e., alphacitral (lemon, lime), neral, i.e., beta-citral (lemon, lime), decanal (orange, lemon), aldehyde C-8 (citrus fruits), al
  • the sweeteners may be chosen from the following non-limiting list: glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, xylitol, and the like.
  • hydrogenated starch hydrolysates and the synthetic sweetener 3 ,6-dihydro-6-methyl- 1-1-1 ,2,3 -oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.
  • Other sweeteners may also be used.
  • Conventional tableting aids may be selected from a wide variety of materials such as lubricants, glidants, solubility enhancers, crystallization aids, auxiliary binders, anti- caking agents and flow agents. They are present in amounts ranging from about 0% to about 50%, based upon tablet composition weight.
  • lubricants such as magnesium stearate calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene, glyceryl monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, sodium stearyl fumarate, adipic acid, light mineral oil and the like may be employed, with sodium stearyl fumarate preferred.
  • Waxy fatty acid esters such as glyceryl behenate, sold as "Compritol" products, can be used. Mixtures are operable.
  • Glidants such as starch, talc, lactose, stearates, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, Cabosil, Syloid, and silicon dioxide may be employed.
  • lactose at about 0.1% to about 2.0% is prefered.
  • Other useful tableting aids include solubility enhancers, such as the polyethylene glycol-32 (PEG-32) glyceryl ester sold as "Gelucire".
  • the present invention also contemplates the use of crystallization modifiers, with surfactants and ethanol being preferred crystallization modifiers.
  • Other materials which are non-saccharide hydrophilic organic materials e.g., ethanol, may also be used.
  • Useful modifiers preferably have a hydrophilic to lipid balance (HLB) of about 6 or more.
  • HLB hydrophilic to lipid balance
  • Such materials include, without limitation, anionic, cationic, and zwitterionic surfactants as well as neutral materials with suitable HLB values.
  • Hydrophilic materials having polyethylene oxide linkages are effective. Those with molecular weights of at least about 200, preferably at least 400, are highly useful.
  • Crystallization modifiers useful herein include: ethanol, lecithin, polyethylene glycol (PEG), propylene glycol (PG), dextrose, the Spans and Tweens which are commercially available from ICI America, and the surface active agents known as "Carbowax". Generally, the polyoxyethylene sorbitan fatty acid esters called Tweens, or combinations of such modifiers are used. Crystallization modifiers are usually inco ⁇ orated into matrices in amounts of between about 0% and 10%. When ethanol is used, it is contacted with the matrix particles in amounts ranging from about 0.5% to about 10%, based on total matrix weight. The particles are then dried and further processed.
  • auxiliary binders which contribute to the ease of formation and general quality of the tablet.
  • Auxiliary binders include starches, pregelatinized starches, gelatin, polyvinylpyrrolidone, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinyloxoazolidone, and polyvinylalcohols.
  • color additives can be used.
  • Such color additives include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Lakes are dyes adsorbed on aluminum hydroxide or other carriers.
  • the process steps of the present invention require the use of an uncured shearform matrix, that is, a shearform matrix which has not undergone significant recrystallization.
  • the preparation of floss suitable for practicing the present invention is disclosed in co- assigned U.S. Patents 5,380,473 and 5,429,836, both of which are inco ⁇ orated by reference herein.
  • the floss is a "shearform matrix" produced by subjecting a feedstock which contains a sugar carrier to flash-flow processing.
  • the term "shearform” will include flash-heat and flash-shear matrices and will be interchangeably used with the term “floss”, which will include all amo ⁇ hous material, regardless of shape, which is produced by the flash-heat and flash-shear processes.
  • flash-heat One useful apparatus for implementing a flash-heat process is described in copending U.S. application Serial No. 08/854,344, filed May 12, 1997, entitled “Apparatus for Melt Spinning Feedstock Material having a Flow Restricting Ring”. Any other apparatus or physical process which provides similar forces and temperature gradient conditions can also be used.
  • the matrix particles are optionally treated with about 0.1 to about 5% of lactose and/or a crystallization modifier and chopped before other ingredients are added to them.
  • the tablet formulation is compacted/densified before the tableting operation. This pre-tableting compaction/densification step can be performed using any suitable methods which apply force against the shearform matrix and cause the added binding material to migrate internally into the network of floss particles and cause the matrix made from sugar alcohol-containing constituents to become less sticky.
  • the tableting composition containing a binding material is subjected to uniform force, such that the resultant mass is substantially free of surface stickiness.
  • a preferred means of performing this process is roller compaction.
  • Machines useful in the invention include those referred to as "Chilsonator” or "Pharmapaktor". These and similar machines are designed to turn out a compacted mass in a steady, continuous flow at a high rate of speed.
  • Such a machine utilizes two grooved rollers revolving toward each other.
  • the space between the rollers is controlled by hydraulic rams, so that the machine is capable of exerting known pressures on any solid material which flows between the rollers.
  • the speed of rotation of the rollers is also regulated.
  • the solid particulate material is fed between the rollers from a hopper. After passing through the rollers, the compacted mass resembles a thin sheet, the surface of which is substantially free of stickiness.
  • the initial compaction and densification steps are not limited to use of the above techniques. Other suitable machinery and techniques are contemplated, provided they render the exposed floss surface free of stickiness.
  • the compaction processes can be performed at ambient temperature and humidity.
  • Compaction forces may vary depending on the specific tablet formulation. Generally, forces up to about 5,000 psi are applied.
  • the compacted mass is sized to a desired particle size.
  • the resultant particles are free flowing because their surfaces are substantially dry to the touch and do not exhibit the tackiness of the original uncompacted tableting composition. Sizing of the particles to obtain a uniform size further enhances the flowability of these particles. Mesh screens, milling and other such sizing techniques are useful. Mesh sizes may range from about 200 to about 1,500 .
  • optional tableting aids can be inco ⁇ orated into the tableting composition for use in making discrete dosage units. The once sticky uncompacted tableting composition has been thus transformed into free flowing particles.
  • Low pressure forces are typically under 500 psi.
  • High pressure forces are usually above 500 psi and are generally in the range of 1,000 to 6,000 psi.
  • a strong, highly attractive tablet can be produced having a texture and internal structure which is relatively porousfor ease of solubilization. Moreover, the tablet is high in strength because of self-binding properties. When chewable tablets are made, they are compressed to hardness values of about
  • EXAMPLE I A shearform matrix was prepared subjecting a blend of appropriate ingredients to flashflow processing using the device described in U.S. application Serial No. 08/854,344, filed May 12, 1997.
  • the combination included a saccharide-based carrier material, a hydrophilic sugar alcohol and a surfactant. This blend contained:
  • the ingredients were mixed, then subjected to flash-heat processing.
  • the shearform matrix resulting from the processing was reduced in volume by chopping for less than a minute in a Stephan High shear mixer.
  • Example I The shearform matrix of Example I was then combined with various additives.
  • the shearform matrix of Example I was used in the following composition:
  • the glycerine and ibuprofen microspheres were mixed and added to one-fourth of the shearform matrix floss. These ingredients were then mixed in a Hobart mixer for about 1 minute. The remaining three portions of floss were added and mixed in intervals. The flavors, sweeteners and starch were sieved through 20 mesh, then added and mixed for an additional minute. Finally, the color was sieved to 20 mesh, added and mixed until the blend took on a homogeneous color.
  • the blend was then subjected to roller compaction sufficient to internalize the glycerine binder into the floss.
  • the compacted mass was sized using a screen of approximately 20 mesh and mixed again to yield free flowing granulates.
  • the resultant fiowable particulates were then tableted. The tablets integrity and friability were within specified limits.
  • EXAMPLE III An uncured shearform floss was formed, using the process of Example I, from the following composition:
  • the APAP microspheres and glycerine were first mixed for about 1 minute by hand. The floss was chopped and then added to the APAP/glycerine mix and all other ingredients, with mixing.
  • a floss was made from the following formulation via a procedure similar to that of Example I.
  • sucrose, sorbitol, xylitol, and Polysorbate 80 were blended in a Littleford FKM600 mixer for 10 minutes. The blend was then subjected to Shearform process at 60Hz and 250°C temperature using the 5" crown head disclosed in U.S.S.N. 08/854,344, filed May 12, 1997 to make floss particles.
  • the floss was chopped in the Littleford FKM600 mixer with 2% lactose and treated with ethanol (4% of the floss). The floss was dried at 45°C for 90 minutes. The floss was then milled/sieved through a 20 mesh screen using a Fitzmill or Apexmill.
  • Vitamin D 3 100SD 0.18%
  • the calcium carbonate was blended with Vitamin D 3 for 15 minutes at speed 1 in a Littleford FM130.
  • the milled floss, flavor, and acids were added and blended further for 5 minutes.
  • the flow agent was added and blended for additional 2 minutes.
  • the magnesium stearate was added and blended for additional 3 minutes.
  • the blend was then roller compacted using an Alexanderwerk WP50 Roll Compactor/granulator, equipped with two vertically-opposed rolls fed by twin feed screws.
  • the roller speed was maintained at 8 ⁇ m, feed screw speed at 20 rpm and the hydraulic pressure was varied from 25 to 90 bars.
  • the compacted granules had a dual screen size of 1.0 and 2.0 mm.
  • the roller compacted granules were compressed on a Kilian T200 rotary press at 20-30 lbs. hardness, 2.75g tablet weight, 19mm round concave or flat-faced tooling.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention concerne un procédé pour former un mélange coulant pour comprimés, présentant des propriétés cohésives. Ce procédé consiste à mélanger une matrice amorphe et un liant, à densifier ce mélange pour répartir uniformément ledit liant dans ladite matrice amorphe crue et former une masse compactée, et à calibrer ladite masse compactée pour former des particules coulantes d'un mélange. L'invention concerne également des comprimés fabriqués à partir de ces mélanges.
PCT/US1998/017069 1997-08-20 1998-08-18 Procede pour ameliorer l'ecoulement et la compression de compositions de fabrication de comprimes WO1999008659A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU90220/98A AU9022098A (en) 1997-08-20 1998-08-18 Process for improving flow and compression of tableting compositions
JP2000509399A JP2002518291A (ja) 1997-08-20 1998-08-18 錠剤組成物の流動性及び圧縮性の改善方法
EP98942091A EP0996427A1 (fr) 1997-08-20 1998-08-18 Procede pour ameliorer l'ecoulement et la compression de compositions de fabrication de comprimes
CA002301282A CA2301282A1 (fr) 1997-08-20 1998-08-18 Procede pour ameliorer l'ecoulement et la compression de compositions de fabrication de comprimes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91497297A 1997-08-20 1997-08-20
US13298898A 1998-08-12 1998-08-12
US08/914,972 1998-08-12
US09/132,988 1998-08-12

Publications (1)

Publication Number Publication Date
WO1999008659A1 true WO1999008659A1 (fr) 1999-02-25

Family

ID=26830927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017069 WO1999008659A1 (fr) 1997-08-20 1998-08-18 Procede pour ameliorer l'ecoulement et la compression de compositions de fabrication de comprimes

Country Status (5)

Country Link
EP (1) EP0996427A1 (fr)
JP (1) JP2002518291A (fr)
AU (1) AU9022098A (fr)
CA (1) CA2301282A1 (fr)
WO (1) WO1999008659A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001046012A (ja) * 1999-08-06 2001-02-20 Kanebo Ltd 風味改良剤及びそれを用いた錠菓様組成物
US6348264B1 (en) 1998-04-27 2002-02-19 Roquette Freres Process for producing low de starch hydrolysates by nanofiltration fractionation, products obtained thereby, and use of such products
WO2009120080A1 (fr) * 2008-03-26 2009-10-01 Mareda Holding Bv Compositions de chewing-gum contenant des cannabinoïdes
US20100184861A1 (en) * 2006-11-10 2010-07-22 Giovanni Politi Method and apparatus for dry granulation
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
US8968788B2 (en) 2006-11-10 2015-03-03 Atacama Labs Oy Granules, tablets and granulation
US10258576B2 (en) 2004-05-24 2019-04-16 Takeda As Particulate comprising a calcium-containing compound and a sugar alcohol

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015035B1 (ru) * 2005-12-07 2011-04-29 Никомед Фарма Ас Предварительно уплотненные кальцийсодержащие композиции

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570327A1 (fr) * 1992-05-12 1993-11-18 Fuisz Technologies Ltd. Compositions facilement dispersables contenant du polydextrose
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
EP0667147A2 (fr) * 1994-02-10 1995-08-16 Fuisz Technologies Ltd. Procédé et appareil pour fabriquer des comprimés et comprimés préparés par ce procédé
WO1995034290A1 (fr) * 1994-06-14 1995-12-21 Fuisz Technologies Ltd. Unite de prise comestible a dispersion rapide et produit ainsi obtenu
WO1996003128A1 (fr) * 1994-07-26 1996-02-08 Leo Pharmaceuticals Products Ltd. A/S Løvens Kemiske Fabrik Produktionsaktieselskab Preparation de comprimes a base d'acide fusidique
WO1996035564A1 (fr) * 1995-05-09 1996-11-14 Fuisz Technologies, Ltd. Procede et appareil de formation d'unites posologiques comprimees
WO1997000682A1 (fr) * 1995-06-22 1997-01-09 Akzo Nobel N.V. Tablettes compressees de desogestrel sous forme de granules secs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570327A1 (fr) * 1992-05-12 1993-11-18 Fuisz Technologies Ltd. Compositions facilement dispersables contenant du polydextrose
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
EP0667147A2 (fr) * 1994-02-10 1995-08-16 Fuisz Technologies Ltd. Procédé et appareil pour fabriquer des comprimés et comprimés préparés par ce procédé
WO1995034290A1 (fr) * 1994-06-14 1995-12-21 Fuisz Technologies Ltd. Unite de prise comestible a dispersion rapide et produit ainsi obtenu
WO1996003128A1 (fr) * 1994-07-26 1996-02-08 Leo Pharmaceuticals Products Ltd. A/S Løvens Kemiske Fabrik Produktionsaktieselskab Preparation de comprimes a base d'acide fusidique
WO1996035564A1 (fr) * 1995-05-09 1996-11-14 Fuisz Technologies, Ltd. Procede et appareil de formation d'unites posologiques comprimees
WO1997000682A1 (fr) * 1995-06-22 1997-01-09 Akzo Nobel N.V. Tablettes compressees de desogestrel sous forme de granules secs

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348264B1 (en) 1998-04-27 2002-02-19 Roquette Freres Process for producing low de starch hydrolysates by nanofiltration fractionation, products obtained thereby, and use of such products
JP2001046012A (ja) * 1999-08-06 2001-02-20 Kanebo Ltd 風味改良剤及びそれを用いた錠菓様組成物
US10258576B2 (en) 2004-05-24 2019-04-16 Takeda As Particulate comprising a calcium-containing compound and a sugar alcohol
US20100184861A1 (en) * 2006-11-10 2010-07-22 Giovanni Politi Method and apparatus for dry granulation
US8581134B2 (en) 2006-11-10 2013-11-12 Giovanni Politi Method and apparatus for dry granulation
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
US8968788B2 (en) 2006-11-10 2015-03-03 Atacama Labs Oy Granules, tablets and granulation
US9700513B2 (en) 2006-11-10 2017-07-11 Atacama Labs Oy Method and apparatus for dry granulation
US10265272B2 (en) 2006-11-10 2019-04-23 Atacama Labs Oy Method and apparatus for dry granulation
WO2009120080A1 (fr) * 2008-03-26 2009-10-01 Mareda Holding Bv Compositions de chewing-gum contenant des cannabinoïdes
US9023322B2 (en) 2008-03-26 2015-05-05 Stichting Sanammad Chewing gum compositions comprising cannabinoids
US9433601B2 (en) 2008-03-26 2016-09-06 Stichting Sanammad Chewing gum compositions comprising cannabinoids

Also Published As

Publication number Publication date
CA2301282A1 (fr) 1999-02-25
EP0996427A1 (fr) 2000-05-03
AU9022098A (en) 1999-03-08
JP2002518291A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
US6048541A (en) Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6165512A (en) Dosage forms containing taste masked active agents
US5980941A (en) Self-binding shearform compositions
US5840334A (en) Self-binding shearform compositions
US7815937B2 (en) Quick dissolve compositions and tablets based thereon
CA2405190C (fr) Forme posologique orale solide de simethicone
US6270804B1 (en) Sachet formulations
CA2391439C (fr) Forme posologique pour agents actifs a noyau doux et a enveloppe fragile
US20120082729A1 (en) Quick dissolve compositions and tablets based thereon
EP0996427A1 (fr) Procede pour ameliorer l'ecoulement et la compression de compositions de fabrication de comprimes
WO1999008655A1 (fr) Comprimes a desintegration rapide
IE980519A1 (en) Quick disintegrating tablets

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2301282

Country of ref document: CA

Ref country code: CA

Ref document number: 2301282

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998942091

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 509399

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998942091

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998942091

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载